Literature DB >> 11489246

Gene therapy for prostate cancer.

J R Gingrich1, R D Chauhan, M S Steiner.   

Abstract

Basic research continues to unravel the molecular complexity of normal and abnormal biologic processes. The development of means to affect the expression level of genes that promote or contribute to cellular transformation, invasion, and metastasis has spawned the concept of gene therapy. This relatively new field seeks to reverse or suspend the pathologic progression of a variety of diseases including the malignant transformation of prostatic epithelial cells. Initial clinical trials for prostate cancer have thus far shown gene therapy to be relatively safe, although definitive evidence of durable therapeutic efficacy remains to be demonstrated. In this article, recent preclinical research, current therapeutic strategies, and recent results of gene therapy clinical trials for the treatment of prostate cancer are reviewed.

Entities:  

Mesh:

Year:  2001        PMID: 11489246     DOI: 10.1007/s11912-001-0031-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  45 in total

Review 1.  Nonviral gene therapy: promises and challenges.

Authors:  S Li; L Huang
Journal:  Gene Ther       Date:  2000-01       Impact factor: 5.250

Review 2.  Gene therapy for prostate cancer: where are we now?

Authors:  M S Steiner; J R Gingrich
Journal:  J Urol       Date:  2000-10       Impact factor: 7.450

3.  Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

Authors:  M G Sanda; D C Smith; L G Charles; C Hwang; K J Pienta; J Schlom; D Milenic; D Panicali; J E Montie
Journal:  Urology       Date:  1999-02       Impact factor: 2.649

4.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Authors:  J W Simons; B Mikhak; J F Chang; A M DeMarzo; M A Carducci; M Lim; C E Weber; A A Baccala; M A Goemann; S M Clift; D G Ando; H I Levitsky; L K Cohen; M G Sanda; R C Mulligan; A W Partin; H B Carter; S Piantadosi; F F Marshall; W G Nelson
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

5.  Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.

Authors:  D C Yu; G T Sakamoto; D R Henderson
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

6.  Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro.

Authors:  A Heiser; P Dahm; D R Yancey; M A Maurice; D Boczkowski; S K Nair; E Gilboa; J Vieweg
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

7.  Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer.

Authors:  S J Hall; S E Mutchnik; G Yang; T L Timme; Y Nasu; C H Bangma; S L Woo; M Shaker; T C Thompson
Journal:  Cancer Gene Ther       Date:  1999 Jan-Feb       Impact factor: 5.987

8.  Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models.

Authors:  J A Eastham; S H Chen; I Sehgal; G Yang; T L Timme; S J Hall; S L Woo; T C Thompson
Journal:  Hum Gene Ther       Date:  1996-03-01       Impact factor: 5.695

9.  Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches.

Authors:  J T Hsieh; W Luo; W Song; Y Wang; D I Kleinerman; N T Van; S H Lin
Journal:  Cancer Res       Date:  1995-01-01       Impact factor: 12.701

10.  Prostate-specific amplification of expanded polyglutamine expression: a novel approach for cancer gene therapy.

Authors:  T Segawa; H Takebayashi; Y Kakehi; O Yoshida; S Narumiya; A Kakizuka
Journal:  Cancer Res       Date:  1998-06-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.